Literature DB >> 30962171

Association between biomarkers and medication-related osteonecrosis of the jaws: a systematic review.

Vittorio Moraschini1, Daniel Costa Ferreira de Almeida2, Carlos Marcelo Figueredo3, Monica Diuana Calasans-Maia4.   

Abstract

OBJECTIVES: Our aim was to conduct a systematic review (SR) of the literature assessing the role of human biomarkers in the diagnosis or prognostication of medication-related osteonecrosis of the jaws (MRONJ). STUDY
DESIGN: An electronic search without date or language restriction was carried out in PubMed/MEDLINE, the Cochrane Central Register of Controlled Trials, Web of Science, and LILACS for publications until March 2018. In addition, a manual search in the gray literature was conducted. The search process was performed by 2 independent reviewing authors. Eligibility criteria included randomized and nonrandomized clinical trials, prospective or retrospective cohorts, case controls, and case series evaluating the association between biomarkers and MRONJ. The protocol of this SR was registered in PROSPERO under number CRD42018095886.
RESULTS: The search and selection process yielded 19 studies (2 case series, 6 case-control studies, 9 prospective cohort studies, and 2 retrospective studies) published between 2008 and 2018. Twenty-four biomarkers collected from serum, saliva, and urine were investigated by these studies. Eleven biomarkers were possibly related to MRONJ; however, no consensus is observed in the literature with regard to the sensitivity and clinical effectiveness of these biomarkers.
CONCLUSIONS: Although many biomarkers have been associated with MRONJ, the present SR found scarce clinical evidence supporting the use of these biomarkers for the diagnosis and prognosis of MRONJ.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30962171     DOI: 10.1016/j.oooo.2019.02.014

Source DB:  PubMed          Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol


  5 in total

1.  Prevalence and risk factors of medication-related osteonecrosis of the jaw in osteoporotic and breast cancer patients: a cross-sectional study.

Authors:  Ana Laura Soares; Sérgio Simon; Luiz Henrique Gebrim; Afonso Celso P Nazário; Marise Lazaretti-Castro
Journal:  Support Care Cancer       Date:  2019-08-29       Impact factor: 3.603

Review 2.  Is serum C-terminal telopeptide cross-link of type 1 collagen a reliable parameter for predicting the risk of medication-related osteonecrosis of the jaws? A systematic review and meta-analysis of diagnostic test accuracy.

Authors:  Bassel Traboulsi-Garet; Adrià Jorba-García; Octavi Camps-Font; Fabio Abreu Alves; Rui Figueiredo; Eduard Valmaseda-Castellón
Journal:  Clin Oral Investig       Date:  2022-02-06       Impact factor: 3.573

3.  Serum biomarkers for bisphosphonate-related osteonecrosis of the jaw: a prospective clinical study.

Authors:  Jung-Hyun Park; Sura Cho; Sun-Jong Kim; Tae-Dong Jeong; Yeung-Chul Mun; Jin-Woo Kim
Journal:  Osteoporos Int       Date:  2021-09-02       Impact factor: 5.071

4.  The effect of pamidronate delivery in bisphosphonate-naïve patients on neutrophil chemotaxis and oxidative burst.

Authors:  Jeffrey W Chadwick; Howard C Tenenbaum; Chun-Xiang Sun; Robert E Wood; Michael Glogauer
Journal:  Sci Rep       Date:  2020-10-27       Impact factor: 4.379

5.  Combined Administration of Bisphosphonates, Chemotherapeutic Agents, and/or Targeted Drugs Increases the Risk for Stage 3 Medication-Related Osteonecrosis of the Jaw: A 4-Year Retrospective Study.

Authors:  Yuqiong Zhou; Yejia Yu; Yueqi Shi; Mengyu Li; Chi Yang; Shaoyi Wang
Journal:  Biomed Res Int       Date:  2020-10-15       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.